ClinicalTrials.gg
CompletedNCT00542789Updated May 28, 2010Results posted

Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID

A Phase 3 interventional study of Esomeprazole and Placebo in Gastric Ulcer, Duodenal Ulcer and Rheumatoid Arthritis, sponsored by AstraZeneca. Completed at 39 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2010-05-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.

Enrollment
9th of 11
343 · median 400
Started
2007
with 2 others
Phase 3
9 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
10 of 11
AstraZeneca

Among the 11 studies testing esomeprazole in Stomach Ulcer, this one is the 9th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 4th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing esomeprazole in Stomach Ulcer as a file.
02

Study summary

The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers

03

Conditions studied

  • Gastric Ulcer
  • Duodenal Ulcer
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Lumbago

Keywords

  • gastrointestinal
  • GI
  • NSAID
  • Japan
  • Japanese
  • Gastric ulcer
  • duodenal ulcer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical history of gastric and/or duodenal ulcer
  • A diagnosis of a chronic condition (rheumatoid arthritis, osteoarthritis, lumbago,etc) that requires daily NSAID use,at least 20 years of age

Exclusion criteria

Exclusion Criteria:

  • Having gastric or duodenal ulcer in active or healing stage according to the Sakita/Miwa classification
  • History of esophageal, gastric or duodenal surgery
  • Having severe liver disease or chronic renal disease
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
343 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Placebo

  • Experimental
    2

    Esomeprazole 20 mg

    Drug: Esomeprazole

Interventions

  • 20mg once daily oral

    Also known as: Nexium

  • DrugPlacebo

    once daily oral

06

What researchers measure

Primary outcomes

  1. Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period

    The absence of gastric and/or duodenal ulcer throughout the treatment period

    Time frame: each visit up to 24 weeks

Secondary outcomes

  1. Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment

    The absence of gastric and/or duodenal ulcer up to 4 weeks after treatment

    Time frame: up to 4 weeks

  2. Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment

    The absence of gastric and/or duodenal ulcer up to 12 weeks after treatment

    Time frame: up to 12 weeks

07

Results

Posted May 28, 2010

Participant flow

343 randomised participants 341 in Full Analysis set and safety analysis set. Full set used for summaries of baseline char. and efficacy variables. Safety set used for summaries of safety variables. 2 excluded, took no investigational drug or had protocol deviation. 173 Esomeprazole 20 and 168 placebo had baseline information and were summarised.

Participant flow — Overall Study
MilestoneExperimental: Esomeprazole 20 mgComparater: Placebo
Started175168
Completed13490
Not completed4178
Withdrew: Adverse event1817
Withdrew: Withdrawal by subject73
Withdrew: Protocol violation81
Withdrew: Recurrence of gastric ulcer857

Outcome measures

PrimaryAbsence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period

The absence of gastric and/or duodenal ulcer throughout the treatment period

Time frame:
each visit up to 24 weeks
Reported as:
Number · Participants
Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period
ParticipantsExperimental: Esomeprazole 20 mgComparater: Placebo
Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period167112
SecondaryAbsence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment

The absence of gastric and/or duodenal ulcer up to 4 weeks after treatment

Time frame:
up to 4 weeks
Reported as:
Number · Participants
Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment
ParticipantsExperimental: Esomeprazole 20 mgComparater: Placebo
Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment172133
SecondaryAbsence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment

The absence of gastric and/or duodenal ulcer up to 12 weeks after treatment

Time frame:
up to 12 weeks
Reported as:
Number · Participants
Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment
ParticipantsExperimental: Esomeprazole 20 mgComparater: Placebo
Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment168119

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Esomeprazole 20 mg—12/173 (6.9%)134/173 (77.5%)
Comparater: Placebo—5/168 (3%)124/168 (73.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventExperimental: Esomeprazole 20 mgComparater: Placebo
Faeces DiscolouredGastrointestinal disorders0/1731/168
Upper Gastrointestinal HaemorrhageGastrointestinal disorders0/1731/168
Gastroduodenal HaemorrhageGastrointestinal disorders0/1731/168
Pneumonia BacterialInfections and infestations0/1731/168
Gastric CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1731/168
Oesophageal CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1731/168
Haemorrhagic AnaemiaBlood and lymphatic system disorders0/1731/168
Colonic PolypGastrointestinal disorders1/1730/168
EnterocolitisGastrointestinal disorders1/1730/168
VomitingGastrointestinal disorders1/1730/168
Most frequent other events
Showing 10 of 15
Most frequent other events
EventExperimental: Esomeprazole 20 mgComparater: Placebo
NasopharyngitisInfections and infestations27/17327/168
Abdominal Pain UpperGastrointestinal disorders18/17322/168
Stomach DiscomfortGastrointestinal disorders15/17317/168
Abdominal DistensionGastrointestinal disorders15/17311/168
Reflux OesophagitisGastrointestinal disorders10/17313/168
NauseaGastrointestinal disorders11/1739/168
AnorexiaMetabolism and nutrition disorders11/1736/168
DyspepsiaGastrointestinal disorders7/17310/168
DiarrhoeaGastrointestinal disorders9/1736/168
ConstipationGastrointestinal disorders7/1735/168

Baseline characteristics

Age, Customized
Age, Customized(participants)Experimental: Esomeprazole 20 mgComparater: PlaceboTotal
<65 years7891169
Between 65 and 74 years5954113
>=75 years362359
Missing202
Sex/Gender, Customized
Sex/Gender, Customized(participants)Experimental: Esomeprazole 20 mgComparater: PlaceboTotal
Female108100208
Male6568133
Missing202
08

Study locations

39 sites
  • Research Site
    Chiryu, Aichi, Japan
  • Research Site
    Seto, Aichi, Japan
  • Research Site
    Yotukaido, Chiba, Japan
  • Research Site
    Mizumaki, Fukuoka, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Akashi, HYOGOi, Japan
  • Research Site
    Itami, Hyogo, Japan
  • Research Site
    Koto, Hyogo, Japan
  • Research Site
    Nishinomiya, Hyogo, Japan
  • Research Site
    Hitachi, Ibaragi, Japan
  • Research Site
    Morioka, Iwate, Japan
  • Research Site
    Sagamihara, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Nagaokakyo, Kyoto, Japan
  • Research Site
    Chiisagata, Nagano, Japan
  • Research Site
    Matsumoto, Nagano, Japan
  • Research Site
    Sasebo, Nagasaki, Japan
  • Research Site
    Beppu, Oita, Japan
  • Research Site
    Ihara, Okayama, Japan
  • Research Site
    Hirakata, Osaka, Japan
  • Research Site
    Sakai, Osaka, Japan
  • Research Site
    Suita, Osaka, Japan
  • Research Site
    Takatsuki, Osaka, Japan
  • Research Site
    Kawagoe, Saitama, Japan
  • Research Site
    Fukuroi, Shizuoka, Japan
  • Research Site
    Hamamatsu, Shizuoka, Japan
  • Research Site
    Izunokuni, Shizuoka, Japan
  • Research Site
    Maikinohara, Shizuoka, Japan
  • Research Site
    Yaizu, Shizuoka, Japan
  • Research Site
    Shimotsuke, Tochigi, Japan
  • Research Site
    Chiyoda, Tokyo, Japan
  • Research Site
    Koto, Tokyo, Japan
  • Research Site
    Musashimurayama, Tokyo, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Nagano, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Saitama, Japan
  • Research Site
    Shizuoka, Japan
09

References and documents

Publications

  • Sugano K, Kinoshita Y, Miwa H, Takeuchi T; Esomeprazole NSAID Preventive Study Group. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. Aliment Pharmacol Ther. 2012 Jul;36(2):115-25. doi: 10.1111/j.1365-2036.2012.05133.x. Epub 2012 May 16. PubMed 22591121 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2007
First posted
Oct 12, 2007
Start
Aug 2007
CompletionActual
Feb 2009
Results first posted
May 28, 2010
Last update
May 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00542789
Lead sponsor
AstraZeneca
First posted
Oct 12, 2007
Start date
Aug 2007
Completion
Feb 2009
Results posted
May 28, 2010
Last update
May 28, 2010

Study contacts

Naotsugu Oyama
study director · AstraZeneca Japan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion